Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Bruker (BRKR) stock in plain English

Free brief · no signupStart here
BRKRPublished Nov 18, 2026
Bruker Corp
Healthcare · Medical Devices
Sells analytical instruments like nuclear magnetic resonance spectrometers, mass spectrometers, and advanced microscopes.
Assets:
Over 9,700 employeesStaff distributed across research, manufacturing, and global customer support teams.
Primary production sitesKey manufacturing facilities located in Germany, Switzerland, the United States, and Malaysia.
NMR and MS platformsProprietary nuclear magnetic resonance and mass spectrometry systems for chemical analysis.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

49
OPS ScoreOperating finances
Latest quote
-1.83%$62.10
$9.48B
n/a (loss)
$3.51B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was BRKR. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Bruker (BRKR) do?

Bruker Corp (BRKR) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Sells analytical instruments like nuclear magnetic resonance spectrometers, mass spectrometers, and advanced microscopes. It manufactures scientific instruments and diagnostic tools used to analyze materials at molecular, cellular, and. It is worth $9.48B on the market and sold $3.51B over the last year.

Market cap
$9.48B
P/E ratio
None (reported a loss)
Annual sales
$3.51B
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 18, 2026

Brands and businesses behind BRKR

  • MALDI Biotyper: Identifies microorganisms using mass spectrometry and earns through instrument sales, diagnostic test kits, and software subscriptions.
  • Canopy Biosciences: Provides spatial biology instruments and testing services, earning revenue through reagent sales and contracted biomarker research.
  • Inscopix: Produces miniature brain-imaging microscopes, selling hardware and imaging consumables to academic and pharmaceutical researchers.
  • Chemspeed Technologies: Builds laboratory automation hardware and robotics, earning revenue from custom equipment sales and software licenses.

BRKR’s flags, in plain English

Each flag is a number from Bruker’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Insiders Hold

Insiders own 27.2% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Stupid Cash

Can pay this year's bills 1.8 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 48% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -4.8%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about BRKR

How big is Bruker?

Bruker’s market cap is $9.48B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.51B: what customers paid the company over the last year, before any costs.

What is BRKR’s P/E ratio?

BRKR has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with BRKR?

Academic and government research budgets fund a major portion of instrument purchases, leaving sales vulnerable to public spending cuts. That is one risk on Bruker’s card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Bruker’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BRKR’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card